Inspire Medical Systems, Inc. Announces Third Quarter 2026
• AMA CPT® Editorial Panel approved new Category I CPT codes for single lead hypoglossal nerve stimulation, including Inspire V, set to take effect January 1, 2028
- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2026.
“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic. We will stay disciplined in our education initiatives and focused on executing our strategic priorities as we finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.
“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy. With that progress, and the investment capacity we’re redirecting into high- impact revenue growth initiatives through Project Horizon, we believe we are positioned well for growth in the years ahead.”
Third Quarter 2026 Financial Results (Third Quarter 2026 compared to Third Quarter 2025)
• Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in U.S. revenue. The U.S. revenue decline was primarily driven by the adverse impacts of coding and reimbursement challenges.
• Gross margin increased 20 bps to 86.0%, primarily due to increased sales mix of the Inspire V system, which has a higher gross margin than the Inspire IV system.
• Operating expenses increased $23.5 million, or 12.8%, to $206.6 million, primarily due to $24.1 million of restructuring charges, legal settlement expense of $7.0 million, and higher legal fees, partially offset by lower marketing expenses and lower stock-based compensation expense.
• Operating loss was $28.7 million, and operating margin was (13.9)%. Adjusted operating income was $1.9 million, and adjusted operating margin was 0.9%.
• The effective tax rate was 2.5% compared to 26.7%. The decrease in the effective tax rate was primarily driven by the current period pre-tax loss and discrete tax charges related to restructuring. For the three months ended September 30, 2025, the Company maintained a full valuation allowance against federal and state deferred tax assets, which was subsequently released at December 31, 2025.
• Net cash provided by operating activities for the three months ended September 30, 2026 was $46.4 million, compared to $68.5 million in the prior year period. The change was primarily driven by lower net earnings and lower collections on receivables due to the third quarter 2025 cash recovery following temporary issues with the implementation of a new invoice portal and delivery process in the second quarter of 2025.
• As of September 30, 2026, cash, cash equivalents, and investments increased $48.5 million to $453.1 million as compared to December 31, 2025.
The Company is narrowing its previously announced revenue outlook to be in the range of $850 million to $860 million, compared to the previous range of $835 million to $875 million. Additionally, the Company now expects adjusted operating margin to be in the range of 4.5% to 5.5%, diluted EPS to be in the range of $(0.36) to $(0.10) and adjusted diluted EPS to be in the range of $1.20 to $1.40.
The Company’s outlook assumes an effective tax rate of approximately 120% to 175% and an adjusted effective tax rate of 33% to 34%, estimated weighted average diluted shares outstanding of approximately 28.9 million, and capital expenditures between $35 million to $40 million.
The Company's management will host a conference call after market close today, Monday, November 2, 2026, at 5:00 p.m. Eastern Time to discuss these results and answer questions.
https://register-conf.media- server.com/register/BI4b0290b4bb464cecaa0a2b420ca13a02 .
A live webcast of the event can be accessed on https://edge.media- server.com/mmc/p/d84s2zzb/ . A replay of the webcast will be available on https://investors.inspiresleep.com starting approximately two hours after the event and archived on the site for two weeks.
Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
This press release includes non-GAAP financial measures, including without limitation, adjusted operating income, adjusted operating margin, adjusted earnings before income taxes, adjusted income tax expense, adjusted effective tax rate, adjusted net earnings, adjusted net earnings per diluted share ("EPS"), adjusted EBITDA, and adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).
We define adjusted operating income as operating income or loss adjusted for items that are not indicative of our ongoing operations. Operating income is the most directly comparable GAAP financial measure to adjusted operating income. We define adjusted operating margin in this release as adjusted operating income divided by revenue. Operating margin is the most directly comparable GAAP financial measure to adjusted operating margin. Adjusted earnings before income taxes is defined as earnings before income taxes, adjusted for items that are not
indicative of our ongoing operations. Earnings before income taxes is the most directly comparable GAAP financial measure. Adjusted income tax expense is defined as income tax expense, adjusted for items that are not indicative of our ongoing operations. Adjusted effective tax rate is adjusted income tax expense divided by adjusted earnings before income taxes. Income tax expense is the most directly comparable GAAP financial measure. Adjusted net earnings is defined as net earnings or loss, adjusted for items that are not indicative of our ongoing operations. Net earnings or loss is the most directly comparable GAAP financial measure to adjusted net earnings. Adjusted net earnings per diluted share is calculated as adjusted net earnings divided by the diluted weighted average shares outstanding. Net earnings or loss per diluted share is the most directly comparable GAAP financial measure to adjusted net earnings per diluted share. We define adjusted EBITDA as net earnings or loss, less interest and dividend income, net, plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, adjusted for items that are not indicative of our ongoing operations. Net earnings or loss is the most directly comparable GAAP financial measure to adjusted EBITDA. We define adjusted EBITDA margin in this release as adjusted EBITDA divided by revenue. Net earnings or loss margin is the most directly comparable GAAP measure to adjusted EBITDA margin. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.
These non-GAAP financial measures are presented because we believe they are useful indicators of our operating performance and facilitate a more meaningful trend analysis without the distortion of various adjustment items. Management uses these measures principally as measures of our underlying operating performance, trends, and for planning purposes, including the preparation of our annual operating plan and financial projections. We believe these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors, and other interested parties to evaluate companies in our industry. We also believe these non-GAAP financial measures are useful to our management and investors as a measure of comparative operating performance from period to period.
These non-GAAP financial measures should not be considered as an alternative to, or superior to, the most directly comparable GAAP financial measures, as measures of financial performance or cash flows from operations, as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that our future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, capital expenditures, and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs, and cash costs to replace assets being depreciated and amortized. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of non-GAAP financial measures should not be construed to imply that our future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on our GAAP results in addition to using non-GAAP financial measures on a supplemental basis. These measures and their definitions are discussed in more detail below and our definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding estimated financial and non-financial impacts from our strategic growth plan (including without limitation , the extent and manner of the use of investments in revenue growth initiatives as well as the time to complete the strategic growth plan) and potential impacts to our business (including potential actions and solutions, such as the new Category I CPT code for Inspire V set to take effect January 1, 2028 and final 2027 Medicare reimbursement payments, as well as timing of these impacts and any related clarity) associated with coding and reimbursement, and our expectations regarding our future growth prospects and full year 2026 financial outlook (including without limitation expectations for the impacts of coding and reimbursement, revenue, expected growth, adjusted operating margin, net earnings or loss per diluted share, adjusted net earnings per diluted share, effective tax rate, adjusted effective tax rate, weighted average diluted shares outstanding and capital expenditures). In some cases, you can identify forward- looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,” ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward- looking statements. Such risks and uncertainties include, among others: our dependency on our Inspire system for revenues; fluctuations in our financial results and the market price of our common stock; our ability to sustain or increase our profitability and our history of operating losses; commercial success and market acceptance of our Inspire therapy; our ability to achieve and maintain adequate and clear levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies, technologies, and pharmaceuticals in our industry; our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire system; our ability to forecast demand and manage our inventory; our dependence on third-parties; risks related to consolidation in the healthcare industry; our ability to expand, manage, and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the United States; our ability to manage our growth; risks related to product liability claims and warranty claims; our ability to address quality issues that may arise with our Inspire system; any failure of key information technology systems, processes, or sites or damage to or inability to access our physical facilities; any violations of anti-bribery, anti-corruption, and anti-money laundering laws; future needs for additional financing; risks related to our tax assets and changes in tax laws; our ability to timely commercialize or obtain regulatory approvals or certifications for our Inspire therapy and system; U.S. Food and Drug Administration (FDA) or other United States or foreign regulatory actions affecting us or the healthcare industry generally; our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement; and our strategic growth plan may not achieve our intended outcome.
Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations“ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 190,803 $ 104,813 Investments, short-term 137,168 203,455 Accounts receivable, net of allowance for credit losses of $787 and 104,706 119,692 $1,080, respectively Inventories, net 178,960 145,293 Prepaid expenses and other current 15,988 10,399 assets Total current assets 627,625 583,652 Investments, long-term 125,125 96,330 Property and equipment, net 85,635 97,872 Operating lease right-of-use 22,125 23,532 assets Deferred tax assets 74,196 88,667 Other non-current assets 18,327 17,264 Total assets $ 953,033 $ 907,317 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 38,073 $ 36,565 Accrued expenses 59,265 59,490 Total current liabilities 97,338 96,055 Operating lease liabilities, non-current 28,611 29,998 portion Other non-current liabilities 135 104 Total liabilities 126,084 126,157 Stockholders' equity: Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no — — shares issued and outstanding Common Stock, $0.001 par value; 200,000,000 shares authorized; 28,941,555 and 28,579,015 issued and 29 29 outstanding at September 30, 2026 and December 31, 2025, respectively Additional paid-in capital 1,010,235 927,159 Accumulated other comprehensive (loss) -1,449 464 income Accumulated deficit -181,866 -146,492 Total stockholders' equity 826,949 781,160 Total liabilities and stockholders' $ 953,033 $ 907,317 equity
1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.
4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.
1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.
4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.
6 Represents accelerated stock-based compensation expense for certain employees who were retirement eligible in accordance with the implementation of changes to the treatment of equity awards under the Inspire Medical Systems, Inc. 2018 Incentive Award Plan upon the holder's death, disability, or retirement.
2 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.
3 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.
5 Represents a non-cash impairment of a strategic investment. Reconciliation of GAAP Net (Loss) Earnings Margin and Non-GAAP Adjusted EBITDA Margin
1 Net (loss) earnings margin is calculated as net (loss) earnings divided by total revenue.
3 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.
4 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.
7 Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total revenue.
Reconciliation of Full Year 2026 Outlook of Estimated Net (Loss) Earnings per Diluted Share
Outlook Full Tax Rate Year 2026 Outlook Full Year 2026 Low Range High Range Low Range High Range Net (loss) per diluted $(0.36) $(0.10) 175.0% 120.0% share Legal fees1 0.31 0.29 Legal 0.18 0.18 settlement2 Restructuring 0.64 0.64 charges3 Share -0.16 -0.16 forfeitures4 Tax impact of stock-based 0.59 0.55 compensation5 Adjusted net earnings per $1.20 $1.40 34.0% 33.0% diluted share
1 These costs represent legal-related expenses related to (a) a civil investigative demand from the Department of Justice, (b) a patent infringement suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel- tracking class action.
4 Stock-based compensation expense benefit due to share forfeitures related to actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based compensation requires that any excess or deficient tax deduction for stock-based compensation be immediately recorded within income tax expense. Employee stock- based compensation activity, including the exercise of stock options, can be unpredictable and can significantly impact our net earnings, net earnings per diluted share, and effective tax rate. These amounts represent the discrete tax expense recorded as excess tax expense for stock-based compensation.
Full text with the tables
Exhibit 99.1
Inspire Medical Systems, Inc. Announces Third Quarter 2026
Financial Results
•
Third quarter revenue of $206.7 million
•
Third quarter diluted EPS of $(0.84); adjusted diluted EPS of $0.14
•
Third quarter operating cash flow of $46.4 million
• AMA CPT® Editorial Panel approved new Category I CPT codes for single lead
hypoglossal nerve stimulation, including Inspire V, set to take effect January
1, 2028
MINNEAPOLIS, MN - November 2, 2026
- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a
medical technology company focused on the development and commercialization of
innovative, minimally invasive solutions for patients with obstructive sleep
apnea, today reported financial results for the quarter ended September 30,
2026.
“We are pleased to have delivered sequential growth in the third quarter, with
U.S. performance coming in ahead of our expectations. Results suggest that,
despite some lingering headwinds, there is greater comfort among implanting
physicians with the current coding dynamic. We will stay disciplined in our
education initiatives and focused on executing our strategic priorities as we
finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert,
Chairman and CEO of Inspire Medical Systems.
“Looking further ahead, we were also pleased with the AMA Editorial Panel’s
September approval of a new CPT® code for single lead HGNS devices, including
the Inspire V system. When this takes effect in January 2028, a dedicated code
set will give physicians and hospitals enhanced clarity around coding and
reimbursement and, in turn, further enable patient access to Inspire therapy.
With that progress, and the investment capacity we’re redirecting into high-
impact revenue growth initiatives through Project Horizon, we believe we are
positioned well for growth in the years ahead.”
Third Quarter 2026 Financial Results (Third Quarter 2026 compared to Third
Quarter 2025)
• Revenue decreased 7.9% to $206.7 million, driven primarily by a decline in
U.S. revenue. The U.S. revenue decline was primarily driven by the adverse
impacts of coding and reimbursement challenges.
• Gross margin increased 20 bps to 86.0%, primarily due to increased sales mix
of the Inspire V system, which has a higher gross margin than the Inspire IV
system.
• Operating expenses increased $23.5 million, or 12.8%, to $206.6 million,
primarily due to $24.1 million of restructuring charges, legal settlement
expense of $7.0 million, and higher legal fees, partially offset by lower
marketing expenses and lower stock-based compensation expense.
• Operating loss was $28.7 million, and operating margin was (13.9)%. Adjusted
operating income was $1.9 million, and adjusted operating margin was 0.9%.
• The effective tax rate was 2.5% compared to 26.7%. The decrease in the
effective tax rate was primarily driven by the current period pre-tax loss and
discrete tax charges related to restructuring. For the three months ended
September 30, 2025, the Company maintained a full valuation allowance against
federal and state deferred tax assets, which was subsequently released at
December 31, 2025.
• Net loss was $24.4 million and adjusted net earnings was $4.1 million.
• Diluted EPS was $(0.84) and adjusted diluted EPS was $0.14.
Financial Condition
• Net cash provided by operating activities for the three months ended September
30, 2026 was $46.4 million, compared to $68.5 million in the prior year period.
The change was primarily driven by lower net earnings and lower collections on
receivables due to the third quarter 2025 cash recovery following temporary
issues with the implementation of a new invoice portal and delivery process in
the second quarter of 2025.
• As of September 30, 2026, cash, cash equivalents, and investments increased
$48.5 million to $453.1 million as compared to December 31, 2025.
Full Year 2026 Guidance
The Company is narrowing its previously announced revenue outlook to be in the
range of $850 million to $860 million, compared to the previous range of $835
million to $875 million. Additionally, the Company now expects adjusted
operating margin to be in the range of 4.5% to 5.5%, diluted EPS to be in the
range of $(0.36) to $(0.10) and adjusted diluted EPS to be in the range of $1.20
to $1.40.
The Company’s outlook assumes an effective tax rate of approximately 120% to
175% and an adjusted effective tax rate of 33% to 34%, estimated weighted
average diluted shares outstanding of approximately 28.9 million, and capital
expenditures between $35 million to $40 million.
Webcast and Conference Call
The Company's management will host a conference call after market close today,
Monday, November 2, 2026, at 5:00 p.m. Eastern Time to discuss these results and
answer questions.
To access the conference call, please preregister on
https://register-conf.media-
server.com/register/BI4b0290b4bb464cecaa0a2b420ca13a02 .
Registrants will receive confirmation with dial-in details.
A live webcast of the event can be accessed on https://edge.media-
server.com/mmc/p/d84s2zzb/ . A replay of the webcast will be available on
https://investors.inspiresleep.com starting approximately two hours after the
event and archived on the site for two weeks.
About Inspire Medical Systems
Inspire Medical Systems is a medical technology company focused on the
development and commercialization of innovative, minimally invasive solutions
for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy
is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that
provides a safe and effective treatment for moderate to severe obstructive sleep
apnea.
For additional information about Inspire, please visit www.inspiresleep.com .
Use of Non-GAAP Financial Measures
This press release includes non-GAAP financial measures, including without
limitation, adjusted operating income, adjusted operating margin, adjusted
earnings before income taxes, adjusted income tax expense, adjusted effective
tax rate, adjusted net earnings, adjusted net earnings per diluted share
("EPS"), adjusted EBITDA, and adjusted EBITDA margin, which differ from
financial measures calculated in accordance with U.S. generally accepted
accounting principles (“GAAP”).
We define adjusted operating income as operating income or loss adjusted for
items that are not indicative of our ongoing operations. Operating income is the
most directly comparable GAAP financial measure to adjusted operating income. We
define adjusted operating margin in this release as adjusted operating income
divided by revenue. Operating margin is the most directly comparable GAAP
financial measure to adjusted operating margin. Adjusted earnings before income
taxes is defined as earnings before income taxes, adjusted for items that are
not
indicative of our ongoing operations. Earnings before income taxes is the most
directly comparable GAAP financial measure. Adjusted income tax expense is
defined as income tax expense, adjusted for items that are not indicative of our
ongoing operations. Adjusted effective tax rate is adjusted income tax expense
divided by adjusted earnings before income taxes. Income tax expense is the most
directly comparable GAAP financial measure. Adjusted net earnings is defined as
net earnings or loss, adjusted for items that are not indicative of our ongoing
operations. Net earnings or loss is the most directly comparable GAAP financial
measure to adjusted net earnings. Adjusted net earnings per diluted share is
calculated as adjusted net earnings divided by the diluted weighted average
shares outstanding. Net earnings or loss per diluted share is the most directly
comparable GAAP financial measure to adjusted net earnings per diluted share. We
define adjusted EBITDA as net earnings or loss, less interest and dividend
income, net, plus income tax expense, plus depreciation and amortization, plus
stock-based compensation expense, adjusted for items that are not indicative of
our ongoing operations. Net earnings or loss is the most directly comparable
GAAP financial measure to adjusted EBITDA. We define adjusted EBITDA margin in
this release as adjusted EBITDA divided by revenue. Net earnings or loss margin
is the most directly comparable GAAP measure to adjusted EBITDA margin.
Reconciliations of these non-GAAP financial measures to their most directly
comparable GAAP measures are included in this press release.
These non-GAAP financial measures are presented because we believe they are
useful indicators of our operating performance and facilitate a more meaningful
trend analysis without the distortion of various adjustment items. Management
uses these measures principally as measures of our underlying operating
performance, trends, and for planning purposes, including the preparation of our
annual operating plan and financial projections. We believe these measures are
useful to investors as supplemental information and because they are frequently
used by analysts, investors, and other interested parties to evaluate companies
in our industry. We also believe these non-GAAP financial measures are useful to
our management and investors as a measure of comparative operating performance
from period to period.
These non-GAAP financial measures should not be considered as an alternative to,
or superior to, the most directly comparable GAAP financial measures, as
measures of financial performance or cash flows from operations, as a measure of
liquidity, or any other performance measure derived in accordance with GAAP, and
they should not be construed to imply that our future results will be unaffected
by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended
to be a measure of cash flow for management’s discretionary use, as it does not
reflect certain cash requirements such as tax payments, capital expenditures,
and certain other cash costs that may recur in the future. Adjusted EBITDA
contains certain other limitations, including the failure to reflect our cash
expenditures, cash requirements for working capital needs, and cash costs to
replace assets being depreciated and amortized. In evaluating our non-GAAP
financial measures, you should be aware that in the future we may incur expenses
that are the same as or similar to some of the adjustments in this presentation.
Our presentation of non-GAAP financial measures should not be construed to imply
that our future results will be unaffected by any such adjustments. Management
compensates for these limitations by primarily relying on our GAAP results in
addition to using non-GAAP financial measures on a supplemental basis. These
measures and their definitions are discussed in more detail below and our
definition of these non-GAAP financial measures is not necessarily comparable to
other similarly titled captions of other companies due to different methods of
calculation.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical facts are forward-looking statements, including,
without limitation, statements regarding estimated financial and non-financial
impacts from our strategic growth plan (including without limitation , the
extent and manner of the use of investments in revenue growth initiatives as
well as the time to complete the strategic growth plan) and potential impacts to
our business (including potential actions and solutions, such as the new
Category I CPT code for Inspire V set to take effect January 1, 2028 and final
2027 Medicare reimbursement payments, as well as timing of these impacts and any
related clarity) associated with coding and reimbursement, and our expectations
regarding our future growth prospects and full year 2026 financial outlook
(including without limitation expectations for the impacts of coding and
reimbursement, revenue, expected growth, adjusted operating margin, net earnings
or loss per diluted share, adjusted net earnings per diluted share, effective
tax rate, adjusted effective tax rate, weighted average diluted shares
outstanding and capital expenditures). In some cases, you can identify forward-
looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’
‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,”
‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’
‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the negative of these terms or
other similar expressions, although not all forward-looking statements contain
these words.
These forward-looking statements are based on management’s current expectations
and involve known and unknown risks and uncertainties that may cause our actual
results, performance, or achievements to be materially different from any future
results, performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among others: our
dependency on our Inspire system for revenues; fluctuations in our financial
results and the market price of our common stock; our ability to sustain or
increase our profitability and our history of operating losses; commercial
success and market acceptance of our Inspire therapy; our ability to achieve and
maintain adequate and clear levels of coverage or reimbursement for our Inspire
system or any future products we may seek to commercialize; competitive
companies, technologies, and pharmaceuticals in our industry; our ability to
expand our indications and develop and commercialize additional products and
enhancements to our Inspire system; our ability to forecast demand and manage
our inventory; our dependence on third-parties; risks related to consolidation
in the healthcare industry; our ability to expand, manage, and maintain our
direct sales and marketing organization, and to market and sell our Inspire
system in markets outside of the United States; our ability to manage our
growth; risks related to product liability claims and warranty claims; our
ability to address quality issues that may arise with our Inspire system; any
failure of key information technology systems, processes, or sites or damage to
or inability to access our physical facilities; any violations of anti-bribery,
anti-corruption, and anti-money laundering laws; future needs for additional
financing; risks related to our tax assets and changes in tax laws; our ability
to timely commercialize or obtain regulatory approvals or certifications for our
Inspire therapy and system; U.S. Food and Drug Administration (FDA) or other
United States or foreign regulatory actions affecting us or the healthcare
industry generally; our ability to establish and maintain intellectual property
protection for our Inspire therapy and system or avoid claims of infringement;
and our strategic growth plan may not achieve our intended outcome.
Other important factors that could cause actual results, performance or
achievements to differ materially from those contemplated in this press release
can be found under the captions “Risk Factors” and "Management's Discussion and
Analysis of Financial Condition and Results of Operations“ in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2025, our Quarterly Report
on Form 10-Q for the quarter ended June 30, 2026, and as such factors may be
updated from time to time in our other filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov and the Investors page of our
website at www.inspiresleep.com. These and other important factors could cause
actual results to differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking statements
represent management’s estimates as of the date of this press release. While we
may elect to update such forward-looking statements at some point in the future,
unless required by applicable law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Thus, one should not assume that
our silence over time means that actual events are bearing out as expressed or
implied in such forward-looking statements. These forward-looking statements
should not be relied upon as representing our views as of any date after the
date of this press release.
Investor and Media Contact
Brian Johnston or Louisa Smith
Gilmartin Group
[email protected]
Inspire Medical Systems, Inc.
Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)
Three Nine
Months Months
Ended Septem… Ended Septe…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Reve… $ 206,695 $ 224,5… $ 611,8… $ 642,904
Cost
of 28,837 31,773 85,630 97,154
goods
sold
Gross 177,858 192,7… 526,2… 545,750
prof…
Oper…
expe…
Rese…
and 22,176 24,211 72,700 78,223
deve…
Sell…
gene… 184,398 158,8… 483,8… 462,684
and
admi…
Total
oper… 206,574 183,0… 556,5… 540,907
expe…
Oper…
(los… -28,716 9,644 -30,3… 4,843
inco…
Inte…
and
divi… -3,897 -3,973 -11,3… -13,521
(inc…
net
Other
expe… 191 66 527 2,986
net
(Los…
earn…
befo… -25,010 13,551 -19,4… 15,378
inco…
taxes
Inco…
tax -616 3,619 15,876 6,046
(ben…
expe…
Net
(los… $ -24,394 $ 9,932 $ -35,3… $ 9,332
earn…
Basic
(los…
earn… $ -0.84 $ 0.34 $ -1.23 $ 0.32
per
share
Dilu…
(los…
earn… $ -0.84 $ 0.34 $ -1.23 $ 0.31
per
share
Weig…
aver…
shar…
outs…
Basic 28,929… 29,33… 28,82… 29,512…
Dilu… 28,929… 29,60… 28,82… 29,938…
Inspire Medical Systems, Inc.
Consolidated Balance Sheets (unaudited)
(in thousands, except share and per share amounts)
September 30,
2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current assets:
Cash and cash equivalents $ 190,803 $ 104,813
Investments, short-term 137,168 203,455
Accounts receivable, net of
allowance
for credit losses of $787 and 104,706 119,692
$1,080,
respectively
Inventories, net 178,960 145,293
Prepaid expenses and other
current 15,988 10,399
assets
Total current assets 627,625 583,652
Investments, long-term 125,125 96,330
Property and equipment, net 85,635 97,872
Operating lease right-of-use 22,125 23,532
assets
Deferred tax assets 74,196 88,667
Other non-current assets 18,327 17,264
Total assets $ 953,033 $ 907,317
Liabilities and stockholders'
equity
Current liabilities:
Accounts payable $ 38,073 $ 36,565
Accrued expenses 59,265 59,490
Total current liabilities 97,338 96,055
Operating lease liabilities,
non-current 28,611 29,998
portion
Other non-current liabilities 135 104
Total liabilities 126,084 126,157
Stockholders' equity:
Preferred Stock, $0.001 par
value;
10,000,000 shares authorized; no — —
shares
issued and outstanding
Common Stock, $0.001 par value;
200,000,000 shares authorized;
28,941,555 and 28,579,015 issued
and 29 29
outstanding at September 30,
2026 and
December 31, 2025, respectively
Additional paid-in capital 1,010,235 927,159
Accumulated other comprehensive
(loss) -1,449 464
income
Accumulated deficit -181,866 -146,492
Total stockholders' equity 826,949 781,160
Total liabilities and
stockholders' $ 953,033 $ 907,317
equity
Inspire Medical Systems, Inc.
GAAP to Non-GAAP Reconciliations (unaudited)
(in thousands, except per share amounts)
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … … … …
… … … … … …
… …
$ … $ $ % … … … … $ $
— % — … …
— % — … …
— % — … …
— % — … …
— % — — …
$ … $ $ % … … … … $ $
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … … … …
… … … … … …
$ … $ $ % … … … … $ $
— % — … …
$ … $ $ % … … … … $ $
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.
3 Restructuring charges related to Project Horizon.
4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.
Inspire Medical Systems, Inc.
GAAP to Non-GAAP Reconciliations (unaudited)
(in thousands, except per share amounts)
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … … … …
… … … … … …
… …
$ … $ $ % … … … … $ $
— % — … …
— % — … …
— % — … …
— % — … …
— % — — …
$ … $ $ % … … … … $ $
…
…
…
…
…
…
──────────────────────────────────────────────────────────────────────────────
… … … … … …
… … … … … …
$ … $ $ % … … … … $ $
— % — … …
— % — … …
— % … … —
$ … $ $ % … … … … $ $
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.
3 Restructuring charges related to Project Horizon.
4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.
6 Represents accelerated stock-based compensation expense for certain employees
who were retirement eligible in accordance with the implementation of changes to
the treatment of equity awards under the Inspire Medical Systems, Inc. 2018
Incentive Award Plan upon the holder's death, disability, or retirement.
7 Represents a non-cash impairment of a strategic investment.
Reconciliation of GAAP Net (Loss) Earnings to Non-GAAP Adjusted EBITDA
Three Nine
Months Months
Ended Septem… Ended Septem…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
(loss) $ -24,394 $ 9,932 $ -35,374 $ 9,332
earni…
Inter…
and
divid… -3,897 -3,973 -11,377 -13,5…
incom…
net
Income
tax -616 3,619 15,876 6,046
expen…
Depre…
and 5,140 3,677 14,847 10,135
amort…
EBITDA -23,767 13,255 -16,028 11,992
Stock…
compe… 26,917 29,468 88,832 102,2…
expen…
Legal 3,567 1,289 8,700 3,025
fees2
Legal 7,000 — 7,000 —
settl…
Restr… 24,138 — 24,138 —
charg…
Asset
impai… — — — 4,046
charg…
Adjus… $ 37,855 $ 44,012 $ 112,642 $ 121,3…
EBITDA
1 Total stock-based compensation expense.
2 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.
3 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.
4 Restructuring charges related to Project Horizon.
5 Represents a non-cash impairment of a strategic investment.
Reconciliation of GAAP Net (Loss) Earnings Margin and Non-GAAP Adjusted EBITDA
Margin
Three Nine
Mont… Months
Ended Ended
Sept… Septe…
30, 30,
2026 2025 2026 2025
Net
(lo… -11.8 % 4.5 % -5.8 % 1.5 %
ear…
mar…
Int…
and
div… -1.9 % -1.8 % -1.9 % -2.1 %
inc…
net
Inc…
tax -0.3 % 1.6 % 2.6 % 0.9 %
exp…
Dep…
and 2.5 % 1.6 % 2.4 % 1.6 %
amo…
Sto…
com… 13.0 % 13.1 % 14.7 % 15.9 %
exp…
Leg… 1.7 % 0.6 % 1.4 % 0.5 %
fee…
Leg… 3.4 % — % 1.1 % — %
set…
Res… 11.7 % — % 3.9 % — %
cha…
Ass…
imp… — % — % — % 0.6 %
cha…
Adj…
EBI… 18.3 % 19.6 % 18.4 % 18.9 %
mar…
1 Net (loss) earnings margin is calculated as net (loss) earnings divided by
total revenue.
2 Total stock-based compensation expense.
3 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.
4 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.
5 Restructuring charges related to Project Horizon.
6 Represents a non-cash impairment of a strategic investment.
7 Adjusted EBITDA margin is calculated as Adjusted EBITDA divided by total
revenue.
Full Year 2026 Outlook
Reconciliation of Full Year 2026 Outlook of Estimated Net (Loss) Earnings per
Diluted Share
to Adjusted Net Earnings per Diluted Share
Outlook Full Tax Rate
Year 2026 Outlook Full
Year 2026
Low Range High Range Low Range High Range
Net (loss)
per diluted $(0.36) $(0.10) 175.0% 120.0%
share
Legal fees1 0.31 0.29
Legal 0.18 0.18
settlement2
Restructuring 0.64 0.64
charges3
Share -0.16 -0.16
forfeitures4
Tax impact of
stock-based 0.59 0.55
compensation5
Adjusted net
earnings per $1.20 $1.40 34.0% 33.0%
diluted share
1 These costs represent legal-related expenses related to (a) a civil
investigative demand from the Department of Justice, (b) a patent infringement
suit that we filed against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah,
Inc. ("Nyxoah"), and (c) a patent infringement suit brought against us by
Nyxoah.
2 Legal settlement expense associated with the proposed settlement of a pixel-
tracking class action.
3 Restructuring charges related to Project Horizon.
4 Stock-based compensation expense benefit due to share forfeitures related to
actions of Project Horizon.
5 The accounting standards codification guidance governing employee stock-based
compensation requires that any excess or deficient tax deduction for stock-based
compensation be immediately recorded within income tax expense. Employee stock-
based compensation activity, including the exercise of stock options, can be
unpredictable and can significantly impact our net earnings, net earnings per
diluted share, and effective tax rate. These amounts represent the discrete tax
expense recorded as excess tax expense for stock-based compensation.